Tema Etfs LLC Takes Position in Blueprint Medicines Co. (NASDAQ:BPMC)

Tema Etfs LLC acquired a new stake in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 22,474 shares of the biotechnology company's stock, valued at approximately $1,960,000.

A number of other large investors have also added to or reduced their stakes in BPMC. R Squared Ltd acquired a new position in shares of Blueprint Medicines during the fourth quarter worth $51,000. Headlands Technologies LLC bought a new stake in shares of Blueprint Medicines in the 4th quarter valued at about $65,000. Thematics Asset Management acquired a new stake in shares of Blueprint Medicines in the fourth quarter valued at about $72,000. Covestor Ltd increased its stake in shares of Blueprint Medicines by 62.7% in the fourth quarter. Covestor Ltd now owns 973 shares of the biotechnology company's stock valued at $85,000 after buying an additional 375 shares during the period. Finally, Asset Management One Co. Ltd. acquired a new position in shares of Blueprint Medicines in the fourth quarter worth approximately $88,000.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on BPMC shares. Jefferies Financial Group started coverage on shares of Blueprint Medicines in a research report on Monday, March 17th. They set a "buy" rating and a $135.00 target price for the company. Morgan Stanley initiated coverage on shares of Blueprint Medicines in a research note on Thursday, March 20th. They set an "equal weight" rating and a $100.00 target price for the company. Scotiabank initiated coverage on shares of Blueprint Medicines in a report on Friday, March 7th. They issued a "sector outperform" rating and a $150.00 target price on the stock. JMP Securities reiterated a "market outperform" rating and set a $125.00 price target on shares of Blueprint Medicines in a report on Friday, February 14th. Finally, Wolfe Research assumed coverage on Blueprint Medicines in a research note on Tuesday, March 18th. They issued an "outperform" rating on the stock. Five equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $126.56.

Blueprint Medicines Stock Down 1.4%

Shares of Blueprint Medicines stock traded down $1.49 during trading hours on Wednesday, reaching $101.51. The company's stock had a trading volume of 489,733 shares, compared to its average volume of 780,275. The company has a market capitalization of $6.56 billion, a P/E ratio of -93.99 and a beta of 0.83. The stock's fifty day simple moving average is $90.13 and its two-hundred day simple moving average is $94.53. Blueprint Medicines Co. has a one year low of $73.04 and a one year high of $121.90. The company has a debt-to-equity ratio of 1.15, a quick ratio of 2.80 and a current ratio of 2.85.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The biotechnology company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.32). The business had revenue of $149.41 million during the quarter, compared to the consensus estimate of $158.31 million. Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. Blueprint Medicines's revenue was up 55.5% compared to the same quarter last year. During the same period in the previous year, the business posted $1.40 EPS. On average, research analysts forecast that Blueprint Medicines Co. will post -1.28 earnings per share for the current year.

Insider Activity

In other news, COO Christina Rossi sold 2,274 shares of the stock in a transaction dated Monday, May 5th. The shares were sold at an average price of $101.75, for a total value of $231,379.50. Following the completion of the sale, the chief operating officer now owns 66,992 shares in the company, valued at $6,816,436. This represents a 3.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Ariel Hurley sold 2,752 shares of the firm's stock in a transaction dated Monday, May 5th. The shares were sold at an average price of $103.13, for a total transaction of $283,813.76. Following the transaction, the insider now directly owns 16,944 shares in the company, valued at $1,747,434.72. The trade was a 13.97% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 12,777 shares of company stock worth $1,256,490 over the last 90 days. 4.21% of the stock is currently owned by corporate insiders.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.